Страна: САЩ
Език: английски
Източник: NLM (National Library of Medicine)
QUETIAPINE FUMARATE (UNII: 2S3PL1B6UJ) (QUETIAPINE - UNII:BGL0JSY5SI)
NuCare Pharmaceuticals, Inc.
QUETIAPINE FUMARATE
QUETIAPINE 25 mg
ORAL
PRESCRIPTION DRUG
Quetiapine is indicated for the treatment of schizophrenia. The efficacy of quetiapine in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). The effectiveness of quetiapine for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [ see Clinical Studies (14.1) ]. Quetiapineis indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [ see Clinical Studies (14.2) ]. Quetiapine is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adul
Quetiapine tablets, USP 25 mg Peach coloured, film coated, round shape, biconvex tablets, debossed with "262 ” on one side and plain on other side. Bottles of 30 tablets NDC 68071-1892-3 Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59° to 86°F) [See USP].
Abbreviated New Drug Application
QUETIAPINE FUMARATE- quetiapine fumarate tablet NuCare Pharmaceuticals, Inc. ---------- 17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Medication Guide) Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with quetiapine and should counsel them in its appropriate use. A patient Medication Guide about “Antidepressant Medicines, Depression and other Serious Mental Illness, and Suicidal Thoughts or Actions” is available for quetiapine. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document. Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking quetiapine. Increased Mortality in Elderly Patients with Dementia-Related Psychosis Patients and caregivers should be advised that elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at increased risk of death compared with placebo. Quetiapine is not approved for elderly patients with dementia-related psychosis [see Warnings and Precautions (5.1)] . Suicidal Thoughts and Behaviors Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms Прочетете целия документ
QUETIAPINE FUMARATE- QUETIAPINE FUMARATE TABLET NUCARE PHARMACEUTICALS, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE QUETIAPINE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR QUETIAPINE TABLETS. QUETIAPINE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1997 WARNING: INCREASEDMORTALITYINELDERLYPATIENTS WITHDEMENTIA- RELATEDPSYCHOSIS;ANDSUICIDAL THOUGHTSANDBEHAVIORS _SEEFULLPRESCRIBING INFORMATIONFORCOMPLETEBOXEDWARNING._ _ _ INCREASEDMORTALITYIN ELDERLYPATIENTSWITHDEMENTIA-RELATED PSYCHOSIS · ELDERLY PATIENTS WITHDEMENTIA-RELATEDPSYCHOSIS TREATEDWITH ANTIPSYCHOTICDRUGSAREATANINCREASEDRISKOFDEATH.QUETIAPINE TABLETS IS NOT APPROVED FORELDERLYPATIENTS WITH DEMENTIA-RELATEDPSYCHOSIS (5.1) SUICIDALTHOUGHTSANDBEHAVIORS · INCREASEDRISKOFSUICIDALTHOUGHTSANDBEHAVIORIN CHILDREN, ADOLESCENTSANDYOUNGADULTSTAKINGANTIDEPRESSANTS (5.2) · MONITOR FOR WORSENING AND EMERGENCE OF SUICIDAL THOUGHTS AND BEHAVIORS (5.2) RECENT MAJOR CHANGES WarningsandPrecautions,CerebrovascularAdverseReactions,Including Stroke,inElderlyPatientswithDementia-Related Psychosis(5.3) 4/2013 INDICATIONS AND USAGE Quetiapineis an atypical antipsychotic indicated forthetreatmentof: · Schizophrenia (1.1) · BipolarIdisordermanicepisodes (1.2) · Bipolar disorder, depressive episodes (1.2) DOSAGE AND ADMINISTRATION Quetiapine tablets, USP can betakenwithor without food (2.1) Indication Initial Dose Recommended Dose Maximum Dose Schizophrenia-Adults (2.2) 25 mg twice daily 150 to 750 mg/day 750 mg/day Schizophrenia-Adolescents (13 to 17 years) (2.2) 25 mg twice daily 400 to 800 mg/day 800 mg/day Bipolar Mania- Adults Monotherapy or as an adjunct to lithium or divalproex (2.2) 50 mg twice daily 400 to 800 mg/day 800 mg/day Bipolar Mania- Children and Adolescents (10 to 17 years), Monotherapy (2.2) 25 mg twice daily 400 to 600 mg/day 600 mg/day Bipolar Depression-Adults (2.2) 50 mg once daily at bedtime 300 mg/day 300 mg/day _GeriatricUse: _Consider alower starting d Прочетете целия документ